Personalis, Inc.
A cancer genomics company that reads the full DNA of a patient's tumor to help doctors spot cancer returning earlier than scans can. Its flagship test, NeXT Personal, is a liquid biopsy that hunts for tiny traces of tumor DNA in a blood sample. Founded in 2011 by Stanford University researchers, the company's name comes from "personalized" medicine — tailoring cancer care to each patient's unique genetic makeup.
Bought 3.82M
Bought 314.8K
Bought 1.77M
Sold 1.70M
Granted 1.16M · Sold 689.2K
Granted 287.5K · Sold 276.5K
Granted 649.3K · Sold 365.6K
Granted 531.7K · Sold 364.1K
Granted 17.7K · Bought 70.0K · Sold 20.0K
Granted 65.3K · Sold 36.5K
Bought 40.0K · Sold 1
Granted 37.2K
Granted 22.4K · Bought 10.0K
Granted 27.3K
Granted 19.8K
Granted 19.8K
Granted 13.5K
Granted 11.0K
Granted 6.3K
Granted 2.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Tempus AI, Inc.10% owner · 15 transactions | — | 13.04M | — | 3.82M | — |
| Eggers Barry +6 co-filersAffiliate of 10% Owner · 3 transactions | — | 8.17Mas of Mar 2022 | — | 314.8K | — |
| Janmohamed Arif +5 co-filersAffiliate of 10% Owner · 3 transactions | — | 7.85Mas of Aug 2020 | — | 1.77M | — |
| Eggers Barry +9 co-filers10% owner · 2 transactions | — | 6.08Mas of Jun 2019 | — | — | — |
| Abingworth LLPFormer 10% Owner · 11 transactions | — | 3.75Mas of Oct 2020 | — | — | 1.70M |
| Ericson William W. +4 co-filers10% owner · 7 transactions | — | 2.61Mas of Jun 2019 | — | — | — |
| West John StephenPresident and CEO, Director · 36 transactions | — | 622.4Kas of Dec 2022 | 1.16M | — | 689.2K |
| Hall Christopher MChief Executive Officer, Director · 10 transactions | — | 236.0K | 287.5K | — | 276.5K |
| Tachibana AaronCFO AND COO · 63 transactions | — | 203.8K | 649.3K | — | 365.6K |
| Chen RichardPresident and CMO · 86 transactions | — | 173.9K | 531.7K | — | 364.1K |
| Ludlum KenDirector · 6 transactions | — | 113.5Kas of May 2022 | 17.7K | 70.0K | 20.0K |
| Moore Stephen MichaelSVP and Chief Legal Officer · 19 transactions | — | 92.3K | 65.3K | — | 36.5K |
| Ricci PaulDirector · 3 transactions | — | 40.0Kas of Feb 2020 | — | 40.0K | 1 |
| Shoff LonnieDirector · 2 transactions | — | 37.2K | 37.2K | — | — |
| Myers Woodrow A JrDirector · 5 transactions | — | 32.4K | 22.4K | 10.0K | — |
| Bloom Olivia KyusukDirector · 3 transactions | — | 27.3K | 27.3K | — | — |
| Bowman A BlaineDirector · 3 transactions | — | 19.8K | 19.8K | — | — |
| Eastham KarinDirector · 3 transactions | — | 19.8K | 19.8K | — | — |
| Colowick AlanDirector · 2 transactions | — | 13.5Kas of May 2022 | 13.5K | — | — |
| Musil ClintonChief Business Officer · 1 transaction | — | 11.0Kas of Mar 2020 | 11.0K | — | — |
| Widder Kenneth JDirector · 1 transaction | — | 6.3K | 6.3K | — | — |
| MacQuitty JonathanDirector · 1 transaction | — | 2.7Kas of May 2021 | 2.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +2.58M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.